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The ability of naturally infected and cured mice to resist reinfection with tick-transmitted Borrelia burgdorferi
was tested over a 1-year period. All of the mice were resistant to reinfection when they were challenged at 1.5
months after cure. The majority of animals were resistant to reinfection for up to 10.5 months after cure, but
this resistance was lost at 1 year after cure. Both protected and unprotected animals showed a diverse array
of antibodies on Western immunoblots. Protection was not associated with the killing of spirochetes in ticks,
and naturally infected mice produced no antibodies to outer surface protein A (OSP A). The titers to whole
Borrelia sonicate and OSP C, however, remained high throughout the 1-year study period. The levels of
borreliacidal antibodies were highest in the 1.5 month-after-cure group. Natural immunity to reinfection with
B. burgdorferi is limited in time, is complex, and may involve both humoral and cellular components.
Lyme disease is an extremely focal disease; it is hyperen-
demic to areas where populations of infected Ixodes ticks are
found (15). Just a few counties in the Northeast account for the
majority of cases reported each year in the United States (18).
Even within counties where Lyme disease is hyperendemic,
certain communities experience an extremely high risk of
Lyme disease (1, 16), especially where ticks are present in
abundance on residential properties (8, 17). The residents of
communities hard hit by Lyme disease often ask the simple
question of whether someone who has already had Lyme dis-
ease is protected from reinfection with the Lyme disease spi-
rochete.
There are isolated reports in the literature of individuals
who have suffered at least two distinct infections with Borrelia
burgdorferi. Since the discovery of B. burgdorferi as the specific
etiology of Lyme disease (4), at least nine patients have been
reported to be reinfected based on clinical and serological
evidence. In Germany, a patient was infected by tick bite in
1983 and suffered erythema migrans and Bannwarth’s syn-
drome; she was treated and recovered. In 1985, she was bitten
by another tick and suffered erythema migrans again, with a
subsequent rise in antibody titer to B. burgdorferi (20). Pfister
et al. (20) also reviewed four published cases that were con-
sistent with reinfection. An additional case of reinfection with
B. burgdorferi was reported in Germany in 1994 (13), and one
unlucky individual in Austria was infected three times within 4
years (19). In the United States, two children who lived in
Delaware were treated for Lyme arthritis, recovered, and sub-
sequently developed erythema migrans (25).
Although these isolated instances of human reinfection sug-
gest that Lyme disease patients are still at risk of reacquiring
the infection after treatment, few controlled laboratory trials
have addressed this question in animal models. In one report,
mice infected by intradermal B. burgdorferi inoculation were
immune to reinfection for up to 6 months when they were
challenged by intradermal inoculation or with autographs from
infected mice (2). To date, there has been no formal demon-
stration of previous infection and cure providing protection
against subsequent tick-transmitted infection. Moreover, the
longevity of immunity to spirochetes transmitted by the natural
route of infection (tick bite) is unknown. Accordingly, we in-
fected mice by tick bite, cured them, and challenged them by
infected-tick bite over a 1-year period to determine the duration
of immunity to naturally transmitted B. burgdorferi infection.
MATERIALS AND METHODS
Animals. Male outbred Imperial Cancer Research (ICR) mice, 3 weeks of age,
were obtained from the special pathogen-free mouse colony maintained at the
Centers for Disease Control and Prevention laboratory in Fort Collins, Colo.
Infected-tick colony. The Ixodes scapularis tick colony originated from field-
collected females from Great Island, Mass. and Westchester County, N.Y. Un-
infected $F2 generation ticks were infected with the B31 strain of spirochete
(from Shelter Island, N.Y.) by feeding on infected mice as larvae as previously
described (21). Larvae were allowed to molt to nymphs at 21 to 22°C in satu-
rated-humidity conditions. Nymphs were used in these experiments at .1 month
postmolting. The infection rates in this colony were routinely .80%. Ticks were
allowed to feed ad libitum on mice.
Culture of B. burgdorferi. Ticks were examined for spirochetes at 10 to 12 days
after repletion. Individual replete nymphal ticks were disinfected by submersion
in 3% H2O2 and 70% ethanol for 3 min each. Ticks were ground in glass tissue
homogenizers containing 0.25 ml of Barbour-Stoenner-Kelly (BSK) medium.
The homogenate was poured into 6-ml snap-cap tubes containing BSK medium.
A wedge of ear tissue was obtained from each live mouse, or mice were sacrificed
and both ears, the entire urinary bladder, and the heart were obtained. Ear
biopsies were soaked for 15 min in wescodyne and for 15 min in 70% ethanol.
Internal organs were washed rapidly in 70% ethanol. Tissues were finely minced
with scissors and placed into 6-ml snap-cap tubes containing BSK medium. All
cultures were maintained at 33 to 34°C for 1 month and examined at weekly
intervals for viable spirochetes under dark-field microscopy. Contaminated cul-
tures were discarded.
Antibiotic treatment. All of the mice in this study were treated for 2 weeks with
tetracycline by the availability of drinking water ad libitum containing 1 mg/ml.
Water bottles were wrapped with tinfoil to diminish light exposure and replen-
ished every 1 to 2 days.
ELISA. Assay plates were coated with 100 ng of purified recombinant protein
or whole sonicate per well in 100 ml of 0.1 M carbonate buffer (pH 9.6), and
plates were incubated overnight at 4°C. Plates were washed five times in Tris-
buffered saline–0.5% Tween 20 (TBS-t). Wells were blocked with 300 ml of
TBS-t–3% fetal bovine serum (blocking buffer) for 30 min at 37°C. Serum was
diluted in blocking buffer as noted above, and 100 ml/well was incubated at 37°C
for 1 h. Plates were washed five times with TBS-t. Secondary antibody, alkaline
phosphatase-conjugated goat anti-mouse immunoglobulin G (IgG) plus IgM
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(Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.), was diluted 1:2,000
in TBS-t, added to assay wells at 100 ml per well, and incubated at 37°C for 90
min. Plates were washed five times with TBS-t, and 100 ml of p-nitrophenyl
phosphate substrate was added to each well and incubated for 30 min at 37°C.
The enzyme reaction was stopped with 100 ml of 5 N NaOH, and plates were read
on an ELISA plate reader. A negative cutoff of 1 standard deviation (SD) above
the mean optical density reading of the preimmunization serum sample from
each mouse was determined. The data reported are the reciprocal endpoint titers
of the doubling dilutions of each serum sample, beginning at 1:125. Recombinant
outer surface protein A (OSP A) was expressed and purified as previously
described (7). Similarly, OSP C from the B31 strain of B. burgdorferi was ex-
pressed in a pET 9c system with a T7 promoter.
Western blot assays. The serum antibody response and monoclonal antibodies
of interest were assayed by Western blot as previously described (12). Samples
were run on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10%
polyacrylamide) preparatory gels at a concentration of 100 mg of protein per gel.
Proteins were electrophoretically transferred to nitrocellulose filters, and filters
were incubated in blocking solution overnight. Filters were loaded into slot
blotters (Immunetics, Inc., Cambridge, Mass.) and assayed with the designated
sample of serum antibody at a final dilution of 1:100. The detection system was
a colorimetric assay based on alkaline phosphatase conjugated to anti-mouse IgG
plus IgM (Kirkegaard & Perry Laboratories, Inc.).
Borreliacidal assay. A simple borreliacidal-antibody test was adapted from a
previously described assay (5). Mouse sera were diluted 1:2 in HEPES buffer (10
mM with 1 mM MgCl2 and 150 mM NaCl2 [pH 7.4]) to obtain a final volume of
20 ml. B. burgdorferi (strain B31) spirochetes grown in BSK-H (Sigma Chemical
Co., St. Louis, Mo.) were washed three times in HEPES buffer, resuspended to
a final concentration of 6 3 106 cells/ml, added in equal volumes to diluted sera,
and incubated at 33°C for 15 to 18 h. After incubation, the number of viable cells
was counted by using phase-contrast microscopy and a Petroff-Hauser counting
chamber. Viability was counted as motility, retention of a characteristic spiro-
chete shape, and absence of membrane blebbing. The percent survival was
determined by comparing the number of viable cells remaining in each sample
per ml with that of the Borrelia control containing 20 ml each of HEPES and B.
burgdorferi cells.
Chronology of experiment. The time course of the experiment is outlined in
Table 1. Briefly, 3-week-old mice were placed into 10 cohorts of seven animals
each; 5 cohorts were exposed to 10 B31-infected nymphal I. scapularis ticks per
mouse, and 5 cohorts (controls) were exposed to 10 uninfected nymphal I.
scapularis ticks. All ticks were allowed to feed to repletion. At 1 month after tick
feeding, ear biopsies were taken to confirm that all of the mice exposed to
infected nymphs had acquired B. burgdorferi infection. All 34 animals tested were
infected. At 2 months after tick feeding, tetracycline treatment of all 10 cohorts
was initiated. The first day of antibiotic treatment was designated day 0 of the
overall experiment. Antibiotic treatment continued for 2 weeks; 2 weeks after the
termination of treatment, the five cohorts previously exposed to B31-infected
nymphs underwent ear punch biopsies. All test animals were ear punch negative
at this point. Individual cohorts of matched test and control mice were chal-
lenged by exposure to 10 B31-infected ticks per mouse at 1.5, 3, 6, 10.5, and 12
months after day 0. At 1 month after challenge, animals were sacrificed and the
remaining ear tissue, heart, and urinary bladder of each animal were cultured in
BSK medium. The eventual number of mice in each cohort varied (from four to
seven) due to the death of some mice during the 15-month course of the
experiment. Replete challenge nymphs were also cultured in BSK medium.
RESULTS
Mice were challenged with B. burgdorferi-infected nymphal
ticks during a 1-year period after cure (Table 1). On the initial
challenge, at 1.5 months after cure, all seven test mice were
resistant to reinfection and all control mice were susceptible
(Table 2). The proportion of mice susceptible to reinfection
remained #1/3 (P ,0.05) through 10.5 months postcure. At 12
months, however, five of six test mice became infected. Thus,
significant immunity to reinfection lasted for ,1 year in these
experiments.
Replete nymphal challenge ticks were cultured to detect the
presence of viable B. burgdorferi spirochetes at 10 to 12 days
after feeding. The majority of replete nymphs derived from
both test and control cohorts were infected (Table 3). No
significant difference was noted in the proportions of test- and
control-derived ticks at any time point. The overall proportions
of spirochete-infected ticks derived from test (90%) and con-
trol (88%) mice were virtually identical.
Serum samples were obtained from all of the mice in the
experiment prior to initial tick exposure and at 1 month after
cure. In addition, serum samples were obtained from each
cohort immediately prior to challenge tick exposure, except for
the cohort exposed at 10.5 months after cure. Characterization
of the antibody responses of individual mice by Western im-
munoblotting revealed that naturally infected mice developed
antibodies against a diverse array of B. burgdorferi antigens
(Fig. 1). Reactivities against 20 to 25 distinct proteins were
visible on Western immunoblots; the intensity and diversity of
the immune response did not decrease from 1 to 12 months
after cure. In addition, no specific activity in protected animals
that was lacking in unprotected animals could be demon-
strated. The reciprocal endpoint titers of individual mice were
determined by ELISA with whole B. burgdorferi sonicate (Fig.
2) or recombinant OSP C (Fig. 3). The antibody response
TABLE 1. Chronology of procedures in challenge experiment
Timea Procedure
22 mo......................................3-week-old mice exposed to infected
(test) or uninfected (control) ticks
21 mo......................................Ear biopsies cultured from all test mice
Day 0........................................Tetracycline treatment of all test and
control mice started
2 wk ..........................................Tetracycline treatment terminated
4 wk ..........................................Ear biopsies cultured from all test mice
1.5 mob.....................................First cohort of test and control mice
challenged with 10 B31 nymphs
3 mo .........................................Second cohort challenged
6 mo .........................................Third cohort challenged
10.5 mo ....................................Fourth cohort challenged
12 mo .......................................Fifth cohort challenged
a Day 0 was set as the first day of antibiotic treatment.
b Ear, heart, and bladder tissues were cultured from each mouse at 1 month
after challenge feeding.
TABLE 2. Duration of immunity to reinfection with tick-
transmitted B. burgdorferi
Time of
challenge (mo)
No. of mice culture positive/no. of
mice examined
Test mice Control mice
1.5 0/7 6/6a
3 1/6 5/5a
6 1/5 7/7a
10.5 2/6 6/6a
12 5/6 4/4
Total 9/30 28/28a
a P , 0.05 (by chi-square test) between results for test and control groups.
TABLE 3. Proportion of challenge ticks infected with B. burgdorferia
Time of
challenge (mo)
No. of ticks positive/no. of ticks
examined (%)
Test Control
1.5 21/30 (70) 27/33 (82)
3 39/44 (89) 31/32 (97)
6 37/42 (88) 37/46 (80)
10.5 44/46 (96) 18/19 (95)
12 48/48 (100) 27/29 (93)
Total 189/210 (90) 140/159 (88)
a Nymphs were cultured 10 to 12 days after repletion.
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remained high throughout the 12-month period after cure. In
fact, some of the highest titers to both whole sonicate and OSP
C were present in the 12-month group. Moreover, unprotected
animals had high titers to both whole sonicate and OSP C. Sera
from a total of four mice were selected at random from among
cured mice at 1 month after cure and tested for antibody to
OSP A; no antibody to OSP A by ELISA was present at the
lowest dilution tested (1:250).
The borreliacidal-antibody levels in prebled serum samples
as well as in serum samples at 1.5, 3, 6, and 12 months after
cure were determined (Table 4). Spirochete survival after ex-
posure to prebled serum was greater than that after exposure
to immune serum (by two-factor analysis of variance, P ,
0.001; F 5 51.1; df 5 1). Moreover, spirochete survival in sera
from mice obtained at 1.5 months after cure, when all of the
animals were protected from reinfection, was lower than that
FIG. 1. Serum antibody responses of mice assayed by Western immunoblotting. Three serum samples from each mouse were included. For each mouse challenged
at 3, 6, or 12 months ($3524), the first lane contained serum obtained before exposure to ticks, the second lane contained serum obtained at 1 month after cure, and
the third lane contained serum obtained immediately before tick reinfection challenge. For the two mice exposed at 1.5 months (3515 and 3516), the first and second
lanes contained sera obtained before exposure to ticks and the third lane contained serum obtained at 1 month after cure. Underlined mouse numbers indicate mice
that were not protected from reinfection. The immunoblot on the left has 21 lanes; lanes 1 and 21 are monoclonal antibody (MAb) markers; lanes 8, 12, 16, and 20
are spacer lanes. The immunoblot on the right has 20 lanes; lanes 1 and 20 are spacer lanes.
FIG. 2. Reciprocal endpoint ELISA titers of mice immediately before rein-
fection challenge. The antigen used was whole B. burgdorferi sonicate. Open
circles, mice protected from reinfection; closed circles, mice susceptible to rein-
fection.
FIG. 3. Reciprocal endpoint ELISA titers of mice immediately before rein-
fection challenge. The antigen used was recombinant OSP C. Open circles, mice
protected from reinfection; closed circles, mice susceptible to reinfection.
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in sera collected later (by two-factor analysis of variance, P ,
0.001; F 5 9.72; df 5 3). Overall, spirochete survival after
exposure to sera from protected animals (mean percent sur-
vival 6 SD, 30.8% 6 21.3%) was lower than that after expo-
sure to sera from unprotected animals (mean percent sur-
vival 6 SD, 42.3% 6 9.8), but the difference was not
significant.
DISCUSSION
From a public health perspective, the present study adds
emphasis to the message that residents of regions where Lyme
disease is hyperendemic must continue to avoid I. scapularis
bites. An extrapolation from our mouse data to humans sug-
gests that even those who have been infected with B. burgdor-
feri, treated, and cured may be fully susceptible to reinfection
during the next transmission season. Avoiding infected ticks
includes limiting contact with heavily forested areas, tucking
pant legs into socks upon entry into infested habitats, judi-
ciously using repellents, inspecting daily for attached ticks dur-
ing the transmission season, and promptly removing those that
are found (22). The primary months of risk are May through
July, when nymphal I. scapularis populations are at their peak
(23). The present study also suggests that persons with prior
histories of Lyme disease and continued exposure should be
candidates to receive test vaccine preparations. These persons
are not protected from reacquiring Lyme disease by their prior
infections. If the vaccine is safe and effective, persons with
prior Lyme disease should be prime candidates, since they
have been proven to be at high risk.
The mechanism of immunity to reinfection observed in nat-
urally infected mice is unknown. One mechanism of immunity
to naturally transmitted infection is clearly present in animals
with high OSP A titers. Such OSP A-directed immunity is due
to the killing of B. burgdorferi within the tick before spirochetes
have a chance to be transmitted to the host (9). This killing
must take place before spirochetes have a chance to convert
their surface proteins from OSP A to OSP C and migrate to
the salivary glands (6, 27). Clearly, the immunity expressed by
mice in the present study was via a mechanism other than OSP
A antibody, since naturally infected and cured mice had no
detectable titers of antibody to OSP A.
The immune response of naturally infected mice in this
experiment resembled that in previous experiments with nat-
urally infected rodents, namely, a diverse response lacking
antibodies to OSP A and including a strong response to OSP C
(10, 12, 24). Since mice produced abundant antibodies to OSP
C and these antibodies have previously been shown to be
protective against natural infection (11), antibodies to OSP C
were likely candidates to afford protection in naturally infected
animals. In the present experiments, however, OSP C titers
remained high (even 1 year after cure) and could not be asso-
ciated with the loss of protection in the 1-year-after-cure
group. Indeed, some of the unprotected animals had the high-
est OSP C titers and the titers to whole Borrelia sonicate and
OSP C were still vigorous even 1 year after treatment.
Although all of the mice exposed to antibiotics in the present
study were presumed to be cured based on a negative ear
biopsy, the possibility that antibiotic treatment decreases the
spirochete load in the host to the point where organisms are
difficult to culture but are still present exists. This phenomenon
has previously been described for dogs (28) and mice (14). If
this was the case in our experiments, the infections seen in
challenged mice may have been due to relapses after treatment
rather than to true reinfection. We are engaged in long-term
studies to see whether mice that are infected by tick bite and
cured via the tetracycline regimen described in this study re-
lapse with infection for up to 1 year after treatment.
The humoral arm of the immune response may be involved
in the protection invoked in natural B. burgdorferi infection.
Low-dose intradermal inoculation of mice with the spirochete
produces a response that lacks antibodies to OSP A (3, 26);
these antibodies protect against subsequent intradermal chal-
lenge when they are passively transferred to naive hosts. More-
over, borreliacidal antibodies were present in the mice in our
study, particularly at the earliest time point (1.5 months) after
cure. However, the possibility that the cellular immune re-
sponse is also involved in protection against tick-transmitted B.
burgdorferi in naturally infected and cured hosts exists. Exper-
iments in which antibodies and various cellular components
from naturally infected animals are separately and jointly
transferred to test animals which are subsequently challenged
by infected-tick bite will help to elucidate the protection af-
forded by the complex immune response to tick-transmitted B.
burgdorferi.
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